Literature DB >> 21700255

Evaluation of culprit saphenous vein graft lesions with optical coherence tomography in patients with acute coronary syndromes.

Periklis Davlouros1, Anastasia Damelou, Vasileios Karantalis, Ioanna Xanthopoulou, Eleni Mavronasiou, Grigorios Tsigkas, George Hahalis, Dimitrios Alexopoulos.   

Abstract

OBJECTIVES: This study sought to assess, with optical coherence tomography (OCT), presumably culprit atherosclerotic lesions of saphenous vein grafts (SVGs) in patients with acute coronary syndromes (ACS).
BACKGROUND: Atherosclerotic lesions of SVGs have been studied in vivo with angioscopy and intravascular ultrasound. However, imaging with OCT, which has a higher resolution than intravascular ultrasound and better penetration than angioscopy, has not been conducted systematically.
METHODS: Using a nonocclusive OCT technique, we performed angiography and OCT of culprit SVG lesions in patients with unstable angina (UA), ST-segment elevation myocardial infarction (STEMI), and non-STEMI. Fibrous and fatty tissue, calcification, thrombus, and plaque rupture were defined according to OCT objective criteria.
RESULTS: Twenty-eight SVGs (average age 14.6 years) in 26 patients were imaged. Lesions on angiography were complex (96.4%), with ulceration in 32.1% and thrombus in 21.4%. OCT disclosed a fibrofatty composition in all lesions, calcification in 32.1%, plaque rupture in 60.7%, and thrombus in 46.4%. Thrombus was progressively more frequent across groups (UA to STEMI, p = 0.003; UA vs. myocardial infarction, p = 0.006). A thin fibrous cap was marginally more frequent in myocardial infarction patients (UA vs. myocardial infarction, p = 0.06; STEMI 100% vs. non-STEMI 53.3% vs. UA 20%, p = 0.03). OCT features of friability were present in 67.9% of SVGs not correlating with clinical presentation.
CONCLUSIONS: OCT of culprit lesions of old SVGs in patients with ACS demonstrates fibrofatty composition, relatively thin fibrous cap, plaque rupture, and thrombus, which correlate with the clinical spectrum of ACS. This suggests that similar mechanisms with native vessels' atherosclerosis may be involved in SVG-related ACS.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21700255     DOI: 10.1016/j.jcin.2011.02.015

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  5 in total

1.  Saphenous vein graft interventions.

Authors:  Emmanouil S Brilakis; Michael Lee; Julinda Mehilli; Konstantinos Marmagkiolis; Josep Rodes-Cabau; Rajesh Sachdeva; Anna Kotsia; George Christopoulos; Bavana V Rangan; Atif Mohammed; Subhash Banerjee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-05

2.  Nodular Calcification in Saphenous Vein Graft Successfully Treated by Percutaneous Coronary Intervention.

Authors:  Ko Yamamoto; Masahiro Natsuaki; Takeshi Serikawa; Masanori Okabe; Yusuke Yamamoto
Journal:  Case Rep Cardiol       Date:  2018-11-08

Review 3.  Thrombus extraction catheters vs. angiojet rheolytic thrombectomy in thrombotic lesions/SV grafts.

Authors:  Dimitrios Alexopoulos; Periklis A Davlouros
Journal:  Curr Cardiol Rev       Date:  2012-08

4.  Saphenous graft atherosclerosis as assessed by optical coherence tomography data for stenotic and non-stenotic lesions from the OCTOPUS registry.

Authors:  Grzegorz M Kubiak; Elżbieta Pociask; Wojciech Wańha; Magdalena Dobrolińska; Paweł Gąsior; Grzegorz Smolka; Andrzej Ochała; Zbigniew Gąsior; Wojciech Wojakowski; Tomasz Roleder
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-06-19       Impact factor: 1.426

5.  Prediction models for different plaque morphology in non-significantly stenosed regions of saphenous vein grafts assessed with optical coherence tomography.

Authors:  Grzegorz M Kubiak; Magdalena Dobrolińska; Elżbieta Pociask; Wojciech Wańha; Paweł Gąsior; Grzegorz Smolka; Andrzej Ochała; Wojciech Wojakowski; Tomasz Roleder
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-12-11       Impact factor: 1.426

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.